National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines and NCCN Compendium Updated

Flash Update Sent November 10, 2010

NCCN has published updates to the NCCN Guidelines™ and NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Kidney Cancer. These NCCN Guidelines are currently available as Version 1.2011.

Significant updates include:

  • For subsequent therapy of kidney cancer with predominant clear cell histology, the category for bevacizumab was changed from a category 2B to category 2A following cytokine therapy and category 2B following tyrosine kinase inhibitor.
  • For systemic therapy of kidney cancer with non-clear cell histology, erlotinib was added with a category 3 designation. In addition, chemotherapy for sarcomatoid only (category 3) was revised to include combination therapy with gemcitabine + doxorubicin, and single-agent capecitabine, floxuridine, fluorouracil, and doxorubicin were removed.

 

Flash Update Sent November 17, 2010

NCCN has published updates to the NCCN Guidelines for Ovarian Cancer. These NCCN Guidelines are currently available as Version 2.2011.

Based on recent clinical trial data, the panel revised the discussion regarding bevacizumab by adding information about the ICON7 trial and the following statement: “Until there are more mature results from GOG 0218 and ICON7, the NCCN Guidelines Panel for Ovarian Cancer does not recommend the routine addition of bevacizumab to upfront therapy with carboplatin/paclitaxel or as maintenance therapy at this time. The NCCN panel encourages participation in ongoing clinical trials that are further investigating the role of anti-angiogenesis agents in the treatment of ovarian cancer, both in the upfront and recurrence settings.”

 

Flash Update Sent November 19, 2010

NCCN has published updates to the NCCN Guidelines for Colon and Rectal Cancers. These NCCN Guidelines are both currently available as Version 2.2011 (Colon) and Version 3.2011 (Rectal).

Based upon recent presentations, the previous footnote related to BRAF mutations was removed and the following footnotes were added to the metastatic section of the NCCN Guidelines for Colon and Rectal Cancers:

  • Footnote in the first-line setting: Patients with a V600E BRAF mutation appear to have a poorer prognosis. Retrospective subset analyses suggest potential benefit from anti-EGFR monoclonal antibodies in the first-line setting with active chemotherapy regardless of V600E mutation status.
  • Footnote after progression on first-line therapy: Patients with a V600E BRAF mutation appear to have a poorer prognosis. Limited available data suggest lack of antitumor activity from anti-EGFR monoclonal antibodies in the presence of a V600E mutation when used after patient has progressed on first-line therapy.
Corresponding information related to BRAF mutations was updated in the Principles of Pathologic Review section.


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved